Crystallization and preliminary X-ray diffraction studies of choline-binding protein F from Streptococcus pneumoniae by Molina, Rafael et al.
crystallization communications
742 doi:10.1107/S1744309107035865 Acta Cryst. (2007). F63, 742–745
Acta Crystallographica Section F
Structural Biology
and Crystallization
Communications
ISSN 1744-3091
Crystallization and preliminary X-ray diffraction
studies of choline-binding protein F from
Streptococcus pneumoniae
Rafael Molina,a Ana Gonza´lez,b
Miriam Moscoso,b Pedro
Garcı´a,b Meike Stelter,c‡
Richard Kahnc and Juan A.
Hermosoa*
aGrupo de Cristalografı´a Macromolecular y
Biologı´a Estructural, Instituto Quı´mica Fı´sica
Rocasolano, CSIC, Serrano 119, 28006 Madrid,
Spain, bDepartamento de Microbiologı´a
Molecular, Centro de Investigaciones
Biolo´gicas, CSIC, Ramiro de Maeztu 9,
28040 Madrid, Spain, and cInstitut de Biologie
Structurale J.-P. Ebel CEA CNRS UJF, Laboratoire
de Cristallographie Macromole´culaire, 41 Rue
Jules Horowitz, 38027 Grenoble CEDEX 1,
France
‡ Present address: Instituto de Tecnologia
Quı´mica e Biolo´gica, Universidade Nova de
Lisboa, 2781-901 Oeiras, Portugal.
Correspondence e-mail: xjuan@iqfr.csic.es
Received 18 May 2007
Accepted 23 July 2007
Choline-binding protein F (CbpF) is a modular protein that is bound to the
pneumococcal cell wall through noncovalent interactions with choline moieties
of the bacterial teichoic and lipoteichoic acids. Despite being one of the more
abundant proteins on the surface, along with the murein hydrolases LytA, LytB,
LytC and Pce, its function is still unknown. CbpF has been crystallized using the
hanging-drop vapour-diffusion method at 291 K. Diffraction-quality ortho-
rhombic crystals belong to space group P21212, with unit-cell parameters
a = 49.13, b = 114.94, c = 75.69 A˚. A SAD data set from a Gd-HPDO3A-
derivatized CbpF crystal was collected to 2.1 A˚ resolution at the gadolinium LIII
absorption edge using synchrotron radiation.
1. Introduction
Streptococcus pneumoniae is a human pathogen responsible for
infectious diseases that have some of the highest indexes of morbidity
and mortality worldwide. This Gram-positive bacterium exhibits an
absolute requirement for choline for growth. The presence of choline
as a component of teichoic acid (TA) in the pneumococcal cell wall
seems to have selected for the acquisition of a specialized domain, the
choline-binding module (CBM), by certain surface proteins. This
domain allows these proteins to specifically anchor themselves to the
cell wall using choline residues (Yother et al., 1992; Yother & White,
1994; Lo´pez & Garcı´a, 2004, and references therein). Moreover,
many host interactions appear to be mediated by choline residues
being recognized by components of the host response (Cundell et al.,
1995; Pepis & Hirschfield, 2003), such as human C-reactive protein
and the PAF receptor (Hermoso et al., 2005 and references therein).
Choline-binding proteins (CBPs) are an important family of pneu-
mococcal surface proteins and include the murein hydrolases LytA,
LytB, LytC and Pce. These enzymes break various bonds in pepti-
doglycan or in teichoic acid (Lo´pez & Garcı´a, 2004). CBPs have been
demonstrated to participate in a series of important biological func-
tions such as cell adhesion, division and virulence (Yother et al., 1992;
Hammerschmidt et al., 1997; Rosenow et al., 1997; Sa´nchez-Beato et
al., 1998; Brooks-Walter et al., 1999). Choline-binding protein F
(CbpF) appears on the surface of the pneumococcal cell wall, bound
to the characteristic choline moieties of the teichoic and lipoteichoic
acids. The function of CbpF is still unknown; the protein carries an N-
terminal signal sequence of 28 amino acids, with the mature form of
the protein (311 amino acids; 36 288 Da) containing a putative
functional module localized at the N-terminus and a CBM at the C-
terminus which attaches the enzyme to the bacterial cell wall.
Comparison of the sequence of the putative functional module
reveals no similarity to any protein other than the CBMs of other
CBPs. In this sense, this N-terminal module of CbpF seems to have
evolved away from the canonical choline-binding repeats (the
homologous repeating units of about 20 amino acids forming the
CBM of the CBPs). Taking into account the fact that CbpF, together
with LytA, LytB, LytC and Pce (Garcı´a et al., 1999), is one of the more
abundant proteins in the pneumococcal cell envelope, it seems clear
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that CbpF must play a relevant role in pneumococcal physiology or
virulence or both. Structure determination should help to understand
the function of this protein and could open new therapeutic prospects
for treating pneumococcal diseases. Here, we present the preliminary
results obtained by X-ray crystallography on the complete CbpF from
S. pneumoniae.
2. Experimental procedures
2.1. CbpF production and purification
The gene spr0337 from the pneumococcal R6 strain, encoding
CbpF protein, was cloned into plasmid pIN-III-A3 (Masui et al.,
1984). The corresponding PCR fragment was amplified with the
oligonucleotides 50-ggaattcatgAATACCACAGGTGGCCGATTTG-
30 and 50-cgggatccCGCAATCGCTTCTTTCATTATTG-30, which are
complementary to the 50 and 30 ends, respectively, of the DNA
sequence coding for the mature CbpF protein. The lower case letters
in the oligonucleotides indicate extensions to introduce the appro-
priate restriction sites (EcoRI and BamHI). The start codon and the
sequence complementary to the stop codons are shown in bold. The
resulting recombinant plasmid (pAPM40) harboured the cbpF gene
and its DNA sequence was confirmed using an automated Abi Prism
3700 DNA sequencer (Applied Biosystems). All primers were
synthesized on a Beckman Oligo 1000M synthesizer. Restriction
enzymes and other DNA-modifying enzymes were purchased from
Amersham. For the purification of the mature protein, the recom-
binant Escherichia coli DH5 (pAPM40) strain was cultured in
Terrific Broth (Sambrook et al., 1989) containing ampicillin
(100 mg ml1) at 310 K with aeration; when the culture reached an
OD600 of about 0.8, protein expression was induced with 50 mM
isopropyl -d-thiogalactopyranoside and incubation was continued at
the lower temperature of 298 K for 16 h in order to minimize the
presence of inclusion bodies. Cells were collected by centrifugation,
suspended in 20 mM sodium phosphate buffer pH 6.9 and disrupted
by passage twice through a French press (7.6 MPa). The cell lysate
was centrifuged and nucleic acids were separated from protein using
streptomycin sulfate precipitation (Weissborn et al., 1994). The
soluble fraction was loaded onto a DEAE-cellulose column equili-
brated with 20 mM sodium phosphate buffer pH 6.9 in order to purify
CbpF protein by a one-step purification procedure according to
Sa´nchez-Puelles et al. (1990). The homogeneity of the protein pre-
parations was confirmed by SDS–PAGE and mass spectroscopy. Pure
and highly concentrated fractions were pooled and extensively
dialyzed against 20 mM Tris buffer pH 8.0 containing 140 mM choline
chloride. This high concentration of choline (140 mM) in the dialysis
buffer is essential; at lower choline concentrations the protein
precipitated rapidly. The enzyme was then concentrated at 277 K with
a 10 kDa cutoff protein concentrator (Amicon, YM-10) to approxi-
mately 8 mg ml1. The final protein concentration was determined by
UV spectrophotometry assuming a molar absorption coefficient of
152 640M1 cm1 at 280 nm.
2.2. Mass spectrometry
MALDI–TOF measurements were performed using a Voyager
DE-PROmass spectrometer from Applied Biosystems equipped with
a pulsed nitrogen laser ( = 337 nm, 3 ns pulse width, 20 Hz
frequency) and a delayed-extraction ion source. Ions generated by
laser desorption were introduced into the flight tube (1.3 m flight
path) with an acceleration voltage of 25 kV in the linear positive-ion
mode. All mass spectra were collected by averaging the signals from
5000 laser shots.
2.3. Crystallization
The initial crystallization conditions were established utilizing the
sparse-matrix sampling technique (Jancarik & Kim, 1991) and the
hanging-drop vapour-diffusion method at 291 K using commercial
screens (Index Screen and Crystal Screens I and II) from Hampton
Research. Initial drops consisted of 1 ml protein solution (7.8 mg ml1
in 20 mM Tris–HCl pH 8.0, 140 mM choline chloride) and 1 ml well
solution and were equilibrated against 500 ml well solution. Two
crystal habits (I and II) were obtained using different crystallization
conditions. Habit I crystals were grown in 0.2M ammonium sulfate,
30% PEG 8000 and 0.1M sodium cacodylate buffer pH 6.5 (Fig. 1a)
and habit II crystals were produced in 0.01M NiCl2, 20% PEGMME
2000, 0.1M Tris pH 8.5 (Fig. 1b). Considering the superior diffraction
of the habit II crystals (see Results and discussion), the crystallization
conditions of habit II crystals were optimized by mixing 3 ml protein
solution (3.9 mg ml1 in 20 mM Tris–HCl pH 8.0, 140 mM choline
chloride) and 1 ml well solution, producing crystals with maximum
dimensions of 0.7  0.4  0.3 mm in 3 d that diffracted X-rays to
1.67 A˚ resolution.
2.4. X-ray diffraction experiments
Diffraction data sets from native crystals of both habits were
collected on a MAR 345 image-plate detector using Cu K X-rays
crystallization communications
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Figure 1
The two CbpF crystal habits obtained after crystallization trials. (a) Crystal habit I.
These crystals were grown at 291 K in 0.1M sodium cacodylate pH 6.5, 0.2M
ammonium sulfate, 30% PEG 8000. (b) Crystal habit II was obtained at the same
temperature with 0.1M Tris pH 8.5, 0.01M NiCl2, 20% PEG MME 2000.
generated by an in-house Enraf–Nonius rotating-anode generator
equipped with a double-mirror focusing system and operated at
40 kVand 90 mA. Crystals were cryoprotected by a quick soak (10 s)
in reservoir solution containing 17%(v/v) glycerol.
An isomorphous Gd-derivative crystal was obtained by cocrys-
tallization using the mother liquor used for native crystals (habit II)
and 50 mM of the neutral gadolinium complex Gd-HPDO3A (Girard
et al., 2003), which produced derivative crystals after 7 d. The optimal
wavelength for data collection was taken as the white line
( = 1.7110 A˚) in the LIII absorption edge of Gd as determined from
an X-ray fluorescence spectrum collected from the derivative crystal.
A SAD data set was collected at 100 K using a CCD detector on
beamline ID29 at the European Synchrotron Radiation Facility
(ESRF). The crystal-to-detector distance was fixed at 110 mm. All
data sets were processed and scaled using XDS (Kabsch, 1988) and
SCALA from the CCP4 package (Collaborative Computational
Project, Number 4, 1994). Data-collection statistics for native crystals
(habits I and II) and the Gd-HPDO3A derivative of CbpF are
summarized in Table 1.
3. Results and discussion
Both crystal habits belong to the orthorhombic space group P21212,
but the resolution limits and unit-cell parameters are different. While
crystals with habit I (unit-cell parameters a = 52.40, b = 115.79,
c = 72.98 A˚) diffract X-rays to 1.95 A˚ (Fig. 2a), crystals of habit II
(unit-cell parameters a = 49.13, b = 114.94, c = 75.69 A˚) diffract to
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Figure 2
X-ray diffraction patterns from CbpF crystals. (a) Crystal habit I (oscillation range
1). (b) Crystal habit II (oscillation range 1). The inset in (a) shows reflections at
2.0 A˚ resolution; in (b) reflections reach the edge of the plate, which corresponds to
1.67 A˚ resolution.
Table 1
Data-collection statistics for native CbpF and Gd-HPDO3A-derivatized CbpF
crystals.
Values in parentheses are for the highest resolution shell.
Native, habit I Native, habit II Gd derivative
Space group P21212 P21212 P21212
Unit-cell parameters
a (A˚) 52.40 49.15 49.54
b (A˚) 115.79 115.01 115.10
c (A˚) 72.98 75.79 76.29
Data collection
Temperature (K) 120 120 100
Wavelength (A˚) 1.5418 1.5418 1.7106
Resolution (A˚) 26.92–2.10
(2.14–2.10)
21.07–1.67
(1.76–1.67)
49.39–2.13
(2.28–2.13)
Total reflections 102654 625729 153121
Unique reflections 25934 50379 24209
Redundancy 3.9 (3.9) 12.4 (11.5) 6.3 (4.3)
Completeness (%) 99.9 (100) 99.1 (96.7) 97.5 (87.0)
I/(I) 11.0 (2.3) 33.1 (7.0) 16.3 (7.8)
Rsym† 0.10 (0.56) 0.05 (0.34) 0.07 (0.14)
† Rsym =
P
I  Iavj=
P
I, where the summation is over symmetry-equivalent reflec-
tions.
Figure 3
Plot of the v = 1/2 Harker section of the anomalous Patterson map for the Gd-
HPDO3A derivative. Levels are contoured in 0.5 steps starting at 1.5.
1.67 A˚ resolution (Fig. 2b). Considering the superior resolution of the
diffraction pattern of the habit II crystal, these crystals were used in
the following steps. Considering the molecular weight of CbpF and
the unit-cell volume, a Matthews coefficient of 2.94 A˚3 Da1
(Matthews, 1968) for a monomer in the asymmetric unit and a solvent
content of 58% are obtained. Cocrystallization of CbpF in the
presence of the neutral gadolinium complex Gd-HPDO3A (Girard et
al., 2003) led to derivative crystals of high quality that diffracted
X-rays to 2.13 A˚ resolution. An anomalous Patterson map was
calculated using data in the entire resolution range. The resulting
v = 1/2 Harker section is shown in Fig. 3. Peaks corresponding to Gd-
binding sites were clearly observed in anomalous Patterson maps and
four sites were located using SHELX (Sheldrick, 1998). Initial phases
were calculated at 2.13 A˚ resolution using the program SHARP (de
La Fortelle & Bricogne, 1997). Model building of the complete
modular CbpF is currently in progress.
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